Core Insights - Sika reported a decline in sales for 2025, with total revenues of CHF 11,201.3 million, down 4.8% year-on-year, but achieved a 0.6% growth in local currencies, indicating market share gains across all regions despite challenging conditions in the construction industry [3][5][19] - The company is implementing its Fast Forward program to enhance efficiency and innovation, expecting to generate annual savings of CHF 150 to 200 million by 2028, with a significant portion of these savings anticipated to take effect in 2026 [4][11][10] - Sika's EBITDA margin for 2025 was reported at 18.4%, with an adjusted margin of 19.2% after accounting for one-off costs related to the Fast Forward program, demonstrating strong core business profitability [4][5][17] Financial Performance - Sika's net profit for 2025 was CHF 1,045 million, a decrease of 16.2% from CHF 1,248 million in 2024, with diluted earnings per share falling to CHF 6.50 from CHF 7.76 [5][6][17] - Operating free cash flow was CHF 1,356 million, slightly down from CHF 1,403 million in 2024, but cash conversion improved to 12.1% of sales from 11.9% [5][6][17] - The company proposed an increase in the dividend to CHF 3.70 per share, reflecting a 2.8% year-on-year increase [5][13] Market Dynamics - In the EMEA region, Sika achieved a sales growth of 2.2% in local currencies, with particularly strong performance in the Middle East and Africa [7] - The Americas region also saw a 2.2% increase in sales in local currencies, although the second half of the year faced challenges due to a government shutdown affecting commercial construction [8] - The Asia/Pacific region experienced a decline of 5.3% in local currencies, primarily due to a significant drop in the Chinese construction business, although excluding this segment, the region recorded positive organic growth of 2.5% [9] Strategic Initiatives - The Fast Forward program aims to streamline operations and enhance digital transformation, with targeted structural adjustments in China and efficiency measures in other markets [10][11] - Sika is focused on sustainable performance, achieving a 6.1% reduction in Scope 1 and 2 GHG emissions and improvements in water discharge and waste management [12] - The company remains committed to its medium-term strategic targets for sustainable and profitable growth, with expectations of sales growth of 1% to 4% in local currencies for 2026 [15][16]

Core Insights - Sika reported a revenue of CHF 11,201.3 million for 2025, a decrease of 4.8% compared to 2024, but a 0.6% increase in local currencies, indicating market share gains despite challenging global conditions [3][4][19] - The company is implementing the "Fast Forward" program to enhance organizational agility, innovation, and efficiency, expecting a positive EBITDA effect of CHF 150 to 200 million in the coming years [2][11] - Sika anticipates a revenue growth of 3 to 6% in local currencies for 2026, despite a weaker first half of the year, with an expected EBITDA margin of 19.5 to 20.0% [2][18] Financial Performance - The material margin improved to 54.9% in 2025 from 54.5% in 2024, reflecting a strong focus on cost management and efficiency [4][5] - EBITDA for 2025 was CHF 2,064.7 million, down from CHF 2,269.5 million in 2024, with an EBITDA margin of 18.4%, which would be 19.2% when adjusted for one-time costs related to the Fast Forward program [4][5][19] - Net profit for 2025 was CHF 1,045.3 million, a decrease of 16.2% from CHF 1,247.6 million in 2024, with earnings per share dropping to CHF 6.50 from CHF 7.76 [6][19] Market Dynamics - Sika's largest region, EMEA, saw a revenue growth of 2.2% in local currencies, with strong performance in the Middle East and Africa [7] - In the Americas, revenue growth was also 2.2% in local currencies, impacted by a government shutdown affecting commercial construction [8] - The Asia-Pacific region experienced a decline of 5.3% in local currencies, primarily due to a significant drop in the Chinese construction market, although excluding this, the region showed positive organic growth of 2.5% [9] Strategic Initiatives - The Fast Forward program aims to streamline operations and enhance digital transformation, with expected annual savings of CHF 150 to 200 million starting from 2028, and CHF 80 million anticipated in 2026 [10][11] - Sika is committed to improving its ESG performance, achieving a 6.1% reduction in greenhouse gas emissions and a 14.1% decrease in accidents with lost time [12] Dividend and Governance - The Board of Directors proposed an increase in the gross dividend to CHF 3.70 per share, up 2.8% from the previous year [14] - New board members are proposed for election at the upcoming general meeting, with a focus on enhancing governance and strategic oversight [15]

Core Insights - Sika reported preliminary revenue for 2025 of CHF 11.2 billion, reflecting a decline of 4.8% compared to the previous year, primarily due to currency effects and market challenges [2][7]. Financial Performance - The company achieved a growth of 0.6% in local currencies, with organic growth at -0.4% for the year, and a contribution of 1.0% from acquisitions [2][7]. - The revenue decline in Swiss Francs was influenced by a currency effect of -5.4%, mainly due to a weak US dollar [2][7]. - The EBITDA margin for 2025 is expected to be slightly above 19%, excluding one-time costs related to the "Fast Forward" program [12]. Regional Performance - In the EMEA region, revenue growth was 2.2% in local currencies, with strong performance in the Middle East and Africa, while Southern Europe also showed solid growth [4]. - The Americas region saw a revenue increase of 2.2% in local currencies, although conditions weakened in the second half of the year due to a government shutdown affecting commercial construction [5]. - The Asia/Pacific region experienced a revenue decline of -5.2% in local currencies, heavily impacted by a double-digit revenue drop in the Chinese construction market [6]. Strategic Initiatives - Sika launched the "Fast Forward" program aimed at accelerating innovation and digital transformation, with expected annual savings of CHF 150 to 200 million by 2028, and CHF 80 million in savings anticipated for 2026 [9][10]. - The company has made seven acquisitions in 2025 and is expanding production capacity with seven new factories to enhance growth opportunities [7]. Leadership Changes - At the upcoming General Meeting on March 24, 2026, Barbara Frei and Lukas Gähwiler are proposed for election to the Board of Directors, while Paul Schuler will not seek re-election [11].

Financial Data and Key Metrics Changes - Total revenue for Q2 2025 was $9.2 million, representing a 17% increase from $7.9 million in Q2 2024 [8][10] - Gross margin decreased to 60% in Q2 2025 from 63% in Q2 2024, primarily due to higher inventory reserves [10] - Operating expenses increased by 16% to $11.2 million in Q2 2025 from $9.7 million in Q2 2024 [10][11] - Cash and cash equivalents rose to $41.5 million as of June 30, 2025, compared to $20.1 million at the end of 2024 [11] Business Line Data and Key Metrics Changes - Biologics and Drug Delivery revenue increased by 10% to $4.7 million in Q2 2025, driven by a 12% rise in product revenue and an 8% increase in service revenue [8][9] - Neurosurgery Navigation revenue grew by 33% to $3.4 million, attributed to new product offerings and additional placements [9] - Capital Equipment and Software revenue rose by 11% to $1 million, primarily due to increased service revenue [9] Market Data and Key Metrics Changes - ClearPoint technology is now available at over 100 centers globally, with regulatory clearance in 36 countries [6][24] - The company has activated two new sites in Q2 2025 and expects to activate between 15 and 20 new sites by the end of the year [24] Company Strategy and Development Direction - The company is focused on extending its lead in cell and gene therapy through a comprehensive drug delivery ecosystem [4][5] - Plans to evolve the product portfolio to enhance hospital efficiency and throughput [5] - Aiming to expand the global installed base and generate scale for wider access to ClearPoint technology [6][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued growth across all business pillars, supported by a strong cash position [13][14] - The company is preparing for significant demand as new restorative therapies become available [5][14] - Management highlighted the importance of regulatory approvals and collaborations with biopharma partners for future growth [16][18] Other Important Information - The company has secured foundational funding from Oberlin Capital to support its strategic initiatives [6] - ClearPoint has submitted applications for new ICD-10 codes to assist in tracking commercial use of its technologies [18] Q&A Session Summary Question: Can you provide more details on the biologic partner opportunity and revenue contribution from Cabildy? - Management indicated that while early opportunities are significant, they are not expected to be massive revenue drivers in the near term, serving more as milestones for larger market opportunities [31][32] Question: What is the status of the ClearPoint 3.0 rollout and its impact on margins? - Management confirmed that there is currently no margin impact from ClearPoint 3.0, and the deployment has been the fastest in the company's history, with 35 sites now using the software [36][40] Question: How will MRI suite availability impact the launch of therapies? - Management discussed strategies to improve efficiency in both MRI and operating room settings to mitigate bottlenecks and enhance capacity for procedures [51][53]